Carl Hansen, AbCellera CEO
AbCellera and Canada to invest $500M+ to boost antibody manufacturing and research
AbCellera, a Vancouver-based antibody manufacturer, received an investment from the government of Canada and the province of British Columbia.
The investment will total CA$701 million ($515.9 million) over the next eight years, with the funding going toward building new infrastructure to develop antibody-based medicines. This includes a site to develop and manufacture antibody medicines through the clinic.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters